Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market open
8 197,71 pts
+0.62%


Last updated : 19/11/2026 - 09h35
🏠 Home   ➤    Stock news

Sanofi Receives European Approval for VaxRabeo, Its New Rabies Vaccine

The European Commission has granted VaxRabeo its first marketing authorisation. It covers pre-exposure and post-exposure prophylaxis against rabies for all age groups.

Announced by Sanofi on 19 November 2026, the decision follows the positive opinion issued on 17 September 2026 by the Committee for Medicinal Products for Human Use of the European Medicines Agency.


Sanofi Receives European Approval for VaxRabeo, Its New Rabies Vaccine

A Vaccine Derived from the Same Strain as Verorab and Imovax Rabies

VaxRabeo (inactivated rabies virus, Wistar strain) is produced using Vero cell technology. It shares the same viral strain as Verorab and Imovax Rabies, the rabies vaccines already marketed by Sanofi, which the company presents as a “next-generation” vaccine.

The laboratory states that its formulation is designed to minimise the risk of allergic reactions. It also claims a longer shelf life and better thermostability than its current rabies vaccines: 60 months of storage and stability up to 27 °C for 96 hours before reconstitution.

The approved vaccination schedules include a two-dose pre-exposure prophylaxis, in line with World Health Organization (WHO) recommendations. They also provide for a four-dose post-exposure prophylaxis for unvaccinated individuals, with or without rabies immunoglobulins.

According to WHO estimates cited by Sanofi, rabies is present in 150 countries and causes approximately 59,000 deaths per year worldwide. Around 29 million people receive post-exposure vaccination each year. The disease has no treatment and can only be prevented through vaccination.

Antibody Levels Comparable to the Group's Current Vaccines

The authorisation is based on a clinical programme that compared VaxRabeo with Sanofi's current standard treatments, in both pre-exposure and post-exposure settings, for all age groups and according to WHO schedules. The comparator is therefore the group's existing portfolio, and the published results concern the antibody response.

In pre-exposure settings, the two- and three-dose regimens achieved protective antibody levels comparable to those of the two reference vaccines, in adults as well as children. Booster doses administered 12 months, or 24 to 36 months, after the last dose produced a strong boost of the immune response, according to the press release.

In post-exposure settings, the immunogenicity profile is described as similar, with 100% of participants reaching protective antibody levels after intramuscular administration. The group reports an acceptable safety profile, similar to that of existing vaccines, with no significant safety concern identified, whether the vaccine is administered alone or with immunoglobulins.

Thomas Triomphe, head of Sanofi's Vaccines division, stated: “Deaths from rabies must be prevented at all costs; they are entirely preventable through timely vaccination.”

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Pharmacie, vaccins et santé animale


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 36 550 millions d'euros
  • Quarterly revenue: 36 550 millions d'euros
  • Revenue growth: 13,1 %
  • Net income: 4 979 millions d'euros
  • Free cash flow: 6 993 millions d'euros
  • 12 201 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours